Microsponge Drug Delivery Systems: A Comprehensive Review of Formulation, Characterization and Therapeutic Applications.

Figure 1 SEM images of microsponge A) 600-X magnification of blank PVA microsponge, B) 600-X magnification of blank Tween 80 microsponge, C) 10k-X magnification of PVA based microsponge, D) 10K-X magnification of Tween80 based microsponge, E) 10k-X magnification [12]

Advantages of the Microsponge Drug Delivery System

Microsponge systems offer several clinically and formulation-relevant advantages over conventional drug carriers:

• Unlike microcapsules, which release their entire API payload upon wall rupture without any further modulation, MDDS provides programmable and sustained drug release kinetics, offering superior therapeutic control.
• In contrast to liposomes, which are hindered by low drug payload capacity, complex manufacturing processes, limited chemical stability, and susceptibility to microbial degradation, microsponge systems exhibit broad chemical stability across a wide pH range (1–11) and high resistance to physical and biological degradation.
• MDDS demonstrates thermal stability at temperatures up to 130°C.
• The system supports a drug payload of up to 50–60% by weight.
• Microsponge formulations are free-flowing in nature and economically viable in terms of production costs.
• The porous microsphere architecture enables effective absorption of skin secretions, resulting in reduction of cutaneous oiliness and surface shine ^[2].

Properties of the Actives for the Entrapment into Microsponge

Active pharmaceutical ingredients or excipients intended for entrapment within microsponge systems must satisfy the following physicochemical criteria:

• The active substance must be either fully miscible with the monomer or capable of being rendered miscible through the addition of a small quantity of a water-immiscible organic solvent.
• The substance must be water-immiscible or exhibit only negligible aqueous solubility.
• It must be chemically inert with respect to the monomers and must not cause a significant increase in the viscosity of the reaction mixture during the formulation process.
• It must remain stable in the presence of the polymerization catalyst and under the conditions employed during the polymerization reaction.
• The structural integrity of the spherical microsponge architecture must not be compromised ^[2].
• The active ingredient must demonstrate adequate compatibility with the polymer matrix to facilitate efficient drug loading and controlled release.
• A relatively low molecular weight is preferred to promote diffusion through the porous channels of the microsponge network.
• The substance must not induce premature rupture or mechanical deformation of the microsponge particles.
• The API must retain its pharmacological activity following entrapment and throughout the storage period.
• An appropriate partition coefficient is necessary to ensure retention within the porous structure and facilitate gradual, controlled release.
• The active agent must not adversely alter the porosity or pore size distribution of the loaded microsponge.
• The substance must be amenable to release in a controlled and reproducible manner from the microsponge delivery system.
• The ingredient must exhibit chemical and thermal stability during both the manufacturing process and storage conditions.

Benefits of microsponge tech Microsponge offers following

Microsponge technology confers a spectrum of pharmaceutical and formulation benefits:

• Enhanced therapeutic performance of the active ingredient
• Extended and controlled drug release profiles
• Reduced local irritation and improved patient compliance
• Superior product elegance and cosmetic acceptability
• Improved oil-control, with capacity to absorb oily secretions up to six times the weight of the microsponge without generating a dry or occlusive effect
• Greater formulation flexibility for development of novel dosage forms
• Improved thermal, physical, and chemical stability of the encapsulated active
• Microsponge systems are non-irritating, non-mutagenic, non-allergenic and non-toxic in nature ^[12].

Characteristics of the material entrapped in microsponge

Most liquid or soluble ingredients are amenable to entrapment within microsponge particles; however, such materials must satisfy the following essential requirements:

• They should be either fully miscible with the monomer or capable of being rendered miscible through addition of a small quantity of a water-immiscible solvent.
• They must be chemically inert with respect to the monomers used in fabrication.
• They must be stable under the conditions of polymerization, including exposure to the initiator or catalyst ^[12,13].

Figure 1 CHARACTERISTICS OF MICROSPONGE in microscopic view ^[14]

Drug loading into microsponge can be accomplished through either a one-step or a two-step process, depending on the physicochemical properties of the drug substance. When the drug is an inert, non-polar compound, it serves as a porogen, generating the porous internal structure during polymerization. Such drugs, which do not interfere with or become activated by the polymerization reaction and remain stable to free radical species, are typically incorporated using a one-step process ^[12].

The principal methods employed for microsponge preparation are as follows:

1. Liquid- suspension polymerization: This technique is based on a free radical suspension polymerization approach. As described by Grochowicz et al., the reaction is conducted in a round-bottomed, three-necked flask equipped with a mechanical stirrer a water-cooled condenser and a thermometer. A homogeneous solution of the non-polar drug and the selected monomer(s) is prepared and subsequently combined with an aqueous phase containing a surfactant and a dispersant. Polymerization is initiated through catalysis, elevation of temperature, or addition of a chemical initiator. Water-insoluble pore-forming diluents (porogen) may also be incorporated into the reaction mixture to enhance internal porosity. When the drug is sensitive to polymerization conditions, a two-step procedure is employed. Polymerization results in the formation of cross-linked ladder-like polymer chains; folding of these chains generates spherical particles, and their subsequent agglomeration produces clusters of microspheres which ultimately bind to form the microsponge architecture. Upon completion of polymerization, the liquid porogen diffuses out, leaving behind the porous microsponge matrix. Although operationally convenient, the principal limitation of this method is the potential entrapment of unreacted monomeric residues within the microsponge structure ^[15,16,17].

Figure 2 Liquid-- suspension polymerization ^[15]

Figure 3 Quasi-emulsion solvent diffusion ^[15]

3. Addition of Porogen: In this approach, the internal aqueous phase of the conventional w/o/w double emulsion is replaced by a chemical porogen such as hydrogen peroxide or sodium bicarbonate. The porogen is uniformly dispersed within the polymeric solution to prepare a homogeneous dispersion, which is then re-dispersed in an external aqueous PVA phase. An initiator is subsequently added to the w/o/w emulsion, and the organic solvent is permitted to evaporate, leaving behind the solid microparticles. The use of hydrogen peroxide as the porogen yields evenly distributed and well-interconnected pores with diameters ranging from 5 to 20 μm ^[15,16,19].

Figure 4 Addition of Porogen ^[21]

5. Oil in oil emulsion solvent diffusion: Unlike the w/o/w method, this technique employs an oil-in-oil emulsion in which a volatile organic liquid constitutes the internal phase and is permitted to evaporate gradually under controlled conditions with continuous stirring. This method has been reported using dichloromethane as the internal phase solvent, polylactic-co-glycolic acid (PLGA) as the encapsulating polymer, and a mixture of fixed oil (corn or mineral oil) with dichloromethane containing Span 85 as the external phase. The internal phase is added dropwise to the dispersion medium under constant agitation to form the microsponge particles. This technique has also been applied to the development of hydroxyzine HCl-loaded Eudragit RS-100 microsponge using acetone as the dispersing solvent and liquid paraffin as the continuous medium. The selection of the organic solvent and external phase is dictated by the physicochemical properties of the drug and the polymer chosen for fabrication ^[15,19].

Figure 5 Oil in oil emulsion solvent diffusion ^[15]

6. Lyophilization: Lyophilization has been employed as a secondary step to convert gelation-prepared microspheres into porous particles. In this approach, pre-formed microspheres are incubated in a chitosan hydrochloride solution and subsequently freeze-dried. Rapid solvent removal during the lyophilization cycle promotes pore formation within the microsphere matrix. Although this approach is rapid, it carries the disadvantage of producing structurally compromised particles exhibiting cracking or shrinkage as a result of abrupt solvent elimination ^[15,20].
7. Ultrasound-assisted production: This method was developed through modification of the liquid-liquid suspension polymerization technique, employing β-cyclodextrin (β-CD) as the monomer and diphenyl carbonate as the cross-linking agent for nano sponge synthesis. Particle size control is achieved through a combination of thermal treatment and sonication of the reaction mixture. Following cooling, the resulting product is milled to generate irregularly shaped particles, which are then successively washed with distilled water and ethanol. The cross-linked β-CD porous microparticles serve as effective drug carriers; however, this method presents the disadvantage of potential entrapment of toxic cross-linking agent residues within the matrix ^[15,20,21].
8. Electro-hydrodynamic Atomization Method: Electrohydrodynamic Atomization (EHDA) utilizes a high-voltage electric field to disperse a polymer solution into fine charged droplets, enabling the formation of uniform micro- or nanoparticles upon solvent evaporation. The apparatus consists of a syringe pump, a metallic nozzle a high-voltage power supply and an earthed collector, enclosed within an airflow-regulated chamber to control solvent evaporation and ensure particle uniformity. Various spray regimes—including dripping, cone-jet and multi-jet modes—are employed for droplet generation, with the choice governed by the interplay among electric stress, surface tension and liquid flow rate. The cone-jet mode is particularly suited for producing uniform particles of less than 10 μm diameter. High-viscosity biopolymers such as chitosan present processing challenges due to their tendency to form larger, polydisperse particles; however, this limitation can be addressed by reducing surface tension through appropriate formulation modifications. By systematically optimizing viscosity and surface tension, monodisperse spherical particles suitable for controlled drug release can be reliably produced ^[15,22].

Mechanism of Drug Release

Microsponge systems can be engineered to release predetermined quantities of active substances over a defined period in response to various external stimuli. The principal drug release mechanisms are as follows:

1. pH Triggered release: The surface coating of microsponge particles can be modified to initiate drug release in response to changes in environmental pH. This mechanism has considerable utility in pH-sensitive drug delivery applications across multiple anatomical sites^[23].

2. Temperature Triggered Release: Elevated temperature represents another stimulus capable of activating drug release from the microsponge matrix. At ambient temperatures, certain substances entrapped within the microsponge—such as emollients and sunscreens—may exhibit high viscosity that impedes natural diffusion onto the skin surface. Upon exposure to body heat, solar radiation, or an external heat source, viscosity decreases, thereby enhancing the flow rate of the active substance and facilitating its release ^[23,24].

3. Pressure Triggered Release: Physical compression or mechanical pressure applied to the microsponge matrix results in the release of liquid or active constituents, replenishing the cutaneous supply of the entrapped material. The extent of pressure-induced release is also governed by the resilience and water-retention capacity of the microsponge ^[8].

4. Solubility Triggered Release: In the presence of aqueous media, microsponge systems loaded with water-soluble active substances—such as antimicrobials or deodorants—release their contents through diffusion-mediated processes. The partition coefficient of the active ingredient between the microsponge matrix and the surrounding medium further governs the rate and extent of release ^[8,24–27]..

Figure 6Mechanism of drug release ^[28]

Comprehensive characterization of microsponge systems is indispensable to ensure quality, reproducibility, drug loading capacity, and controlled release behaviour. A range of physicochemical and performance-based evaluation parameters are employed to determine the formulation suitability for pharmaceutical applications ^[1,2].

Particle Size Analysis: Particle size exerts a significant influence on drug release rate, physical stability and dermal penetration characteristics in topical formulations. Microsponge particle size typically falls within the range of 5–300 μm; smaller particles facilitate faster release due to the greater surface area available for diffusion, whereas larger particles provide more prolonged release profiles. Particle size can be determined using optical microscopy, laser diffraction, or dynamic light scattering (DLS). A narrow particle size distribution indicates uniform emulsification conditions during preparation ^[32].

Surface Morphology: The surface morphology of microsponge particles is examined by Scanning Electron Microscopy (SEM), which typically reveals spherical particles with characteristic porous, sponge-like surfaces. The presence of well-defined interconnected pores confirms successful microsponge formation, while surface smoothness and structural integrity are indicative of formulation stability ^[11].

Entrapment Efficiency (EE%): Entrapment efficiency quantifies the proportion of drug successfully incorporated into the microsponge matrix and is calculated using the standard formula:

Elevated EE values reflect favourable drug–polymer compatibility and optimized preparation parameters. Key factors influencing EE% include polymer concentration, drug aqueous solubility, and the stirring speed applied during emulsification ^[1].

Drug Content Analysis: Drug content analysis ensures the homogeneous distribution of API within the microsponge matrix. An accurately weighed sample of microsponge is dissolved in a suitable solvent, filtered, and subjected to spectrophotometric or HPLC analysis. Uniform drug content across production batches is essential for ensuring therapeutic consistency and reproducibility ^[33].

Porosity Determination: Porosity is a critical parameter governing both drug loading capacity and release kinetics; higher porosity facilitates more rapid diffusion of drug molecules.

Porosity can be measured using:

• Mercury intrusion porosimetry
• Liquid displacement method
• Gas adsorption techniques

Controlled and reproducible porosity is a prerequisite for predictable release kinetics ^[34].

In Vitro Drug Release Studies:  In vitro drug release studies are conducted using USP dissolution apparatus (Type I or II), selected according to the dosage form. The microsponge formulation is placed in the appropriate dissolution medium, and aliquots are withdrawn at predetermined time intervals for quantification by UV-Visible spectrophotometry or HPLC. Drug release data are fitted to mathematical kinetic models

• Zero-order kinetics
• First-order kinetics
• Higuchi model
• Korsmeyer–Peppas model

These models help to elucidate the underlying release mechanism (diffusion-controlled, erosion-based, or combined) ^[35].

Production Yield: Production yield indicates the efficiency of preparation method. It is calculated as: add image in between

High production yield is indicative of minimal material losses during formulation processing^.[36]

Compatibility Studies:Drug–polymer compatibility is evaluated using

• Fourier Transform Infrared Spectroscopy (FTIR)
• Differential Scanning Calorimetry (DSC)
• X-ray Diffraction (XRD)

FTIR identifies potential chemical interactions between the API and excipients; DSC detects thermally associated transitions; and XRD characterizes the crystalline or amorphous state of the drug within the microsponge matrix. The absence of significant physicochemical interactions confirms formulation stability ^[37].

True Density and Bulk Density: Density measurements are employed to assess the flow properties and compressibility of microsponge-containing formulations intended for incorporation into tablet or capsule dosage forms. Bulk density, tapped density, Carr’s Compressibility Index, and Hausner Ratio are determined to evaluate powder flow characteristics ^[38].

Zeta Potential: Zeta potential provides an indication of the surface charge of microsponge particles in suspension. High absolute zeta potential values are associated with strong electrostatic repulsion between particles, which confers good physical stability and prevents aggregation. ^[48]

Stability Studies: Stability studies are conducted in accordance with ICH guidelines under accelerated and intermediate storage conditions (e.g., 25°C/60% RH and 40°C/75% RH). Formulations are periodically evaluated for changes in drug content, particle size, morphology, and release behaviour. Stability data are essential for establishing the shelf-life and safety profile of the product ^[39].

Loading Efficiency

The loading efficiency (%) of the microsponge can be calculated according to the following equation:

Loading efficiency = Actual drug content in microsponge / Theoretical drug content × 100 ......(1)

The production yield is determined by comparing the initial total weight of raw materials used in fabrication against the final recovered weight of microsponge (Kilicarslan and Baykara, 2003).

Characterization of Pore Structure ^[12]

The presence and characteristics of internal pores are defining features of microsponge systems and therefore require thorough characterization. Pore volume and pore diameter are critical determinants of the intensity and duration of the release of active substances, as well as of the rate of migration of active ingredients from the microsponge into the surrounding vehicle. Mercury intrusion porosimetry is the preferred technique for investigating the relationship between pore dimensions and drug release kinetics.

Pore diameter

It is calculated by using Washburn equation (Washburn, 1921).

D=-4γcos⁡θP

Where D is the pore diameter (µm); γ the surface tension of mercury (485 dyne cm⁻¹); θ the contact angle (130°); and P is the pressure (psi).

Total pore area (Atot)

It is calculated by using equation,

Atot=1γcos⁡θ0VtotP dV

Where, P is the pressure (psia); V the intrusion volume (ml g⁻¹); Vtot is the total specific intrusion volume (ml g⁻¹).

Average pore diameter (Dm)

It is calculated by using equation,

Dm=4VtotAtot

Where, Vtot is the total specific intrusion volume (ml g⁻¹); Atot is the total pore area.

Envelope (bulk) density (ρse)

It is calculated by using equation,

ρse=WsVp-VHg

Where, Ws is the weight of the microsponge sample (g); Vp the volume of empty penetrometer (ml); VHg is the volume of mercury (ml).

Absolute (skeletal) density (ρsa)

It is calculated by using equation,

ρsa=WsVse-Vtot

Where, Vse is the volume of the penetrometer minus the volume of the mercury (ml).

Percent porosity

It is calculated by equation

Porosity (%)=1ρseρsa×100

Where, ρse is the bulk density; ρsa is the absolute density (Orr, 1969).

FACTORS AFFECTING MICROSPONGE FORMULATION

The pharmaceutical performance of a microsponge drug delivery system is governed by a complex interplay of formulation and process variables. Systematic optimization of these parameters is essential to achieve the desired particle size, porosity, entrapment efficiency, and controlled drug release behaviour.

1. Polymer Type: The selection of polymer is a fundamental determinant of the structural integrity, porosity, and drug release kinetics of the microsponge system. Polymers such as Eudragit RS 100, Eudragit RL 100, ethyl cellulose, and polymethacrylates are widely employed owing to their established biocompatibility and to able permeability. Hydrophobic polymers typically provide sustained drug release, whereas polymers with greater permeability facilitate faster drug diffusion. The molecular weight and intrinsic permeability of the selected polymer exert direct influence on the drug release rate and the mechanical robustness of the microsponge matrix ^[40].
2. Polymer Concentration: Polymer concentration profoundly influences particle size, entrapment efficiency, and drug release profile. Increasing polymer concentration elevates the viscosity of the internal phase, producing larger emulsion droplets and consequently larger microsponge particles. Higher polymer content enhances entrapment efficiency due to the formation of a denser polymeric network; however, excessive polymer may excessively retard drug release. Judicious optimization is therefore required to balance sustained release and adequate therapeutic efficacy ^[41].
3. Drug–Polymer Ratio: The drug-to-polymer ratio directly governs drug loading capacity and release characteristics. Excessively high drug loading may promote an initial burst release attributable to superficial drug deposition on the particle surface. An optimized drug–polymer ratio ensures uniform drug distribution throughout the porous matrix and facilitates controlled diffusion through the interconnected pore channels ^[42].
4. Drug Properties: Physicochemical properties of the drug including aqueous solubility, molecular weight, and chemical stability critically influence microsponge formulation outcomes. Highly water-soluble drugs are prone to significant leaching during preparation, resulting in reduced entrapment efficiency. Lipophilic drugs, by contrast, are generally better suited for microsponge encapsulation due to their stronger affinity for hydrophobic polymer matrices ^[43]. Drug stability in the selected organic solvent system must also be carefully evaluated to prevent degradation during processing ^[1].
5. Type of Solvent: The choice of organic solvent influences droplet formation, polymer precipitation kinetics, and the resulting porosity of the microsponge. Volatile solvents such as dichloromethane and ethanol are commonly employed in quasi-emulsion solvent diffusion methods. The rate of solvent diffusion governs pore formation and internal structural characteristics; rapid solvent removal promotes the formation of highly porous microsponge while slow evaporation tends to yield denser, less porous particles. ^[1]
6. Stirring Speed: Stirring speed during the emulsification step controls emulsion droplet size and, consequently, the final particle size of the microsponge. Higher agitation speeds produce finer droplets, yielding smaller particles with greater surface area and faster drug release rates. Lower stirring speeds generate larger particles associated with more prolonged release profiles. Optimization of stirring speed is therefore essential for achieving the target particle size distribution ^[43].
7. Surfactant Type and Concentration: Surfactants such as polyvinyl alcohol (PVA) function as emulsion stabilizers in the microsponge preparation process. Insufficient surfactant concentration results in particle aggregation, whereas an excess may adversely affect porosity and drug loading. Appropriate surfactant concentrations ensure the formation of uniform well-dispersed particles with consistent physical stability ^[44].
8. Volume of Internal and External Phases: The volumetric ratio of the internal organic phase to the external aqueous phase governs the rate of solvent diffusion and the efficiency of particle formation. A larger external phase volume enhances the solvent diffusion driving force and promotes the formation of highly porous microsponge. An inappropriate phase ratio may result in irregular particle size distribution and reduced production yield. ^[1].
9. Temperature: Processing temperature affects the rate of solvent evaporation and polymer solidification. Elevated temperatures accelerate solvent removal, potentially increasing porosity; however, excessive heat may cause degradation of thermolabile APIs. Controlled and reproducible temperature conditions during formulation are therefore imperative ^[1].
10. Cross-Linking Density: In polymerization-based microsponge preparation, cross-linking density determines the mechanical strength and porosity of the resulting structure. Higher degrees of cross-linking produce rigid, compact architectures with slower drug release, whereas reduced cross-linking yields more porous but structurally less robust particles ^[1].
11. Drying Method: Post-preparation drying conditions—including air drying, vacuum drying, or oven drying—significantly affect the physicochemical properties of the final microsponge product. Rapid or harsh drying may collapse the porous structure, whereas controlled drying conditions preserve the integrity of the pore network. Appropriate drying procedures also prevent particle agglomeration and ensure long-term storage stability ^[45] .

APPLICATION OF MICROSPOGNE DRUG DELIVERY SYSTEM

• The versatile nature of microsponge technology has facilitated its integration into a diverse range of dosage forms including creams, gels, lotions, and oral formulations, thereby demonstrating its broad adaptability across drug delivery requirements. MDDS has been extensively utilized in the management of dermatological disorders such as acne, psoriasis, seborrhoeic dermatitis (dandruff), eczema, scleroderma, alopecia and skin cancer. ^[46]
• These delivery platform enables effective prolonged retention of therapeutics at the application site, enhancing dermal efficacy while minimizing the risks of over- or under-medication that are frequently associated with conventional topical delivery systems. ^[47]
• MDDS also supports the development of gastro retentive systems providing controlled, prolonged drug release with consequent improvements in oral bioavailability and therapeutic outcomes. The technology has been employed for colonic delivery of drugs such as flurbiprofen using pH-responsive coatings, and for enhancing the bioavailability of poorly water-soluble drugs including paracetamol and indomethacin through increased effective surface area. Additionally, MDDS reduces gastrointestinal irritation associated with drugs such as ketoprofen and dicyclomine. Specialized applications include site-specific anticancer drug delivery and regenerative medicine through programmable growth factor release. ^[48,49]
• In the cosmeceutical sector, microsponge technology has transformed the development of sunscreen formulations by enabling encapsulation of UV filters, providing extended photoprotection and improved non-greasy aesthetics. Anti-ageing formulations have also benefited from microsponge-mediated sustained release of retinoids and antioxidants. Coloured cosmetics such as lipsticks and foundation products leverage microsponge encapsulation of pigments for prolonged wear and a matte finish. Consumer products such as moisturizers and anti-acne preparations utilize this platform to provide sustained hydration and reduction of skin irritation. Key clinical and formulation advantages include superior physicochemical stability of sensitive active compounds, enhanced patient compliance, and compatibility with diverse carrier systems, collectively establishing MDDS as a transformative technology for both therapeutic and cosmetic drug delivery innovation^{. [49,50]}

Application and Advantages of MDDS

Table 2 Types of formulations with active agent ^[22,51-58]

Examples of Microsponge Drug Delivery, Their Formulations, and Associated Brands/Trademarks

Table 3 Marketed formulation along with brand and manufacture name. ^[22,59-74]